Qurient Co., Ltd. announced a private placement of 500,000 registered convertible preferred shares at the price of KRW 25,000 per share for gross proceeds of KRW 12,500,000,000 on December 9, 2021. The transaction will include participation from Quad-encore New Knights No. 1 Fund for 380,000 shares, No.

1 of Yukyung Good Thought Bio-Value Specialized Investment Criminal Investment Trust for 40,000 shares, Road 3 Hog Growth Capital Startup Venture Specialized Private Equity Joint Venture Company for 40,000 shares, and CureBio Co.,Ltd. for 40,000 shares. The shares shall be convertible into 500,000 common shares of the company at a conversion price of KRW 25,000 per share. The conversion period will start from December 18, 2022 and ends on December 17, 2026.

The shares shall carry dividend of 1% per annum with cumulative participation conditions. The transaction has been approved by the board of directors of the company.